Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback